[Market Focus] JLK Surges on U.S. FDA Pre-Market Approval for Stroke Analysis Solution

JLK is showing strong performance. This is believed to be influenced by the news that its non-contrast CT (NCCT)-based stroke analysis solution, 'JLK-NCCT', has received 510(k) clearance (pre-market approval) from the U.S. Food and Drug Administration (FDA).

As of 1:56 p.m. on March 26, JLK was trading at 7,660 won, up 4.64% from the previous day.

The company explained that this 510(k) approval is significant because it recognizes the clinical value of AI technology that enables rapid identification and prioritization of suspected stroke patients at the initial non-contrast CT stage, which is the first step in stroke diagnosis.

'JLK-NCCT' is equipped with functions that allow it to both screen patients suspected of cerebral hemorrhage and distinguish those among ischemic stroke patients who are suspected of having large vessel occlusion (LVO) and may need intervention. Notably, while LVO is typically confirmed via CT angiography (CTA), this solution can identify it early at the non-contrast CT stage, supporting rapid triage and response in emergency rooms.

With this 510(k) approval, JLK's strategy to expand its stroke AI portfolio is expected to gain further momentum. Since non-contrast CT is the basic examination most commonly performed first on stroke patients, applying an AI solution at this stage enables a naturally integrated workflow that connects to subsequent tests and treatments, such as CTA, CT perfusion, and MRI.

A company representative stated, "This FDA 510(k) clearance is more than just a regulatory approval," adding, "By enabling AI intervention at the early stage of stroke diagnosis to rapidly screen suspected patients and support patient triage and response, this lays the foundation for further expansion of our sales in the U.S. market going forward."

This content was produced with the assistance of AI translation services.